World M J, Ryle P R, Aps E J, Shaw G K, Thomson A D
Department of Gastroenterology, Greenwich District Hospital, London, U.K.
Alcohol Alcohol. 1987;22(4):331-40.
A prospective randomized double-blind trial of 3-palmitoyl-(+)-catechin at a dose of 1500 mg daily (500 mg t.d.s.) for 3 months vs placebo has failed to demonstrate statistically significant clinical, biochemical or histological benefit in patients with biopsy-proven alcoholic liver disease. Nevertheless, this trial has confirmed the beneficial effect of a reduction in the rate of alcohol consumption on alcoholic liver disease. Apart from clinical evidence of a higher rate of alcohol consumption by patients receiving the active drug during the trial, no adverse side-effects were identified and for this reason, it is suggested that a further trial should be considered with the daily dosage so far used in man (20 mg/kg) increased toward that (100 mg/kg) employed with benefit in animal experiments.
一项前瞻性随机双盲试验，比较每日服用剂量为1500毫克（每日三次，每次500毫克）的3-棕榈酰-（+）-儿茶素持续3个月与安慰剂，结果显示，对于经活检证实的酒精性肝病患者，在临床、生化或组织学方面未显示出统计学上的显著益处。然而，该试验证实了减少酒精摄入量对酒精性肝病具有有益作用。除了在试验期间接受活性药物治疗的患者酒精摄入量较高的临床证据外，未发现不良副作用，因此，建议考虑进一步试验，将迄今为止人体使用的每日剂量（20毫克/千克）提高至动物实验中显示有益效果的剂量（100毫克/千克）。
